Today: 18 November 2025
Subscribe
Browse Category

Mergers & Acquisitions News 29 October 2025 - 3 November 2025

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Stock Price and Intraday Performance (Nov 3, 2025) Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday reuters.com. Prior to the announcement, the stock had closed at $14.37 on Oct. 31 stockanalysis.com, near its 52-week low of ~$14.02 reuters.com reuters.com. The takeover premium (deal valued at ~$21.01 per share) immediately boosted KVUE, though the share price remained a bit below the offer value – typical in cash/stock mergers as arbitragers factor in execution timing and Kimberly-Clark’s own stock movement (KMB shares fell ~12.5% on
3 November 2025
 ·  ·  ·  ·  ·  · 
Merger Showdown: Union Slams Crédit Agricole–Banco BPM Deal Over Job Cuts and “Deserted” Towns

Merger Showdown: Union Slams Crédit Agricole–Banco BPM Deal Over Job Cuts and “Deserted” Towns

Union Sounds Alarm on Bank Merger Italian bank workers’ union First CISL has delivered a stark warning about the rumored merger between Banco BPM and Crédit Agricole Italia. On October 31, the union publicly rejected the potential deal, saying it would come at a high social cost. “An eventual Crédit Agricole–Banco BPM operation will bring a new wave of branch closures [and] heavy cuts to jobs,” cautioned First CISL Secretary General Riccardo Colombani firstcisl.it. He stressed that hundreds of bank branches could shut if the two lenders combine, hurting not only bank employees but also local communities and small businesses
3 November 2025
 ·  ·  ·  · 
Brighthouse Financial (BHF) Stock Soars on Takeover Buzz – Price Jump, Earnings Outlook & Expert Analysis

Brighthouse Financial (BHF) Stock Soars on Takeover Buzz – Price Jump, Earnings Outlook & Expert Analysis

Short-Term and Long-Term Outlook Deal or No Deal: In the short term, Brighthouse’s fate may hinge on the takeover negotiations. If Aquarian finalizes a buyout near $70/share, the stock could quickly gravitate toward that price (roughly 25% above where it traded post-rumor) and shareholders would lock in a substantial one-time gain investing.com. Market watchers note that private equity interest in life insurers is driven by the opportunity to earn higher returns on insurers’ investment portfolios reuters.com. Aquarian’s rumored ~$4 billion offer (at $70) underscores that strategic buyers see more value in Brighthouse than the public market does – a sentiment
31 October 2025
 ·  ·  ·  ·  · 
Chevron (CVX) Stock Rallies on $2B Pipeline Deal – Could $200 Be Next?

Chevron’s Next Big Move: CVX Stock Could Skyrocket on $55B Hess Deal & Low-Carbon Push

In summary, as of Oct 31, 2025 Chevron stands as a dividend-rich, integrated energy leader navigating a weak-oil cycle. Its stock is trading near multi-month lows but backed by record production and cash flow. Short-term catalysts include the Hess synergies and any rebound in oil prices. Longer-term, Chevron emphasizes high-return oil projects (Guyana, Permian) and steady shareholder returns, while gradually investing in lower-carbon ventures. Key factors to watch are global oil demand trends (especially in Asia), OPEC supply decisions, and the results of Q4 earnings (including Exxon, Shell). Analyst consensus sees moderate upside if oil stabilizes, but Chevron – “one of
31 October 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Bidding War Ignites for Obesity Biotech Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bid reuters.com. This move comes just days after the foundation coup at Novo (demanding faster U.S. growth) reuters.com, signaling a full-aggression strategy. Metsera confirmed the offer is “superior” to Pfizer’s, giving Pfizer four business days to respond ts2.tech. Pfizer CEO Albert Bourla has publicly talked up this obesity play, so Pfizer is not likely to concede easily. Unsurprisingly, Pfizer immediately
31 October 2025
 ·  ·  ·  ·  ·  ·  · 
Activist Investor Shocks Wall Street: $10.9B Comerica Sale Sparks Bank M&A Boom

Activist Investor Shocks Wall Street: $10.9B Comerica Sale Sparks Bank M&A Boom

Activist Investors Target Underperforming Banks Until recently, regional banks drew little activist attention. That changed when HoldCo Asset Management loudly challenged Comerica’s board. In July 2025 HoldCo issued a report warning that Comerica and other midsize banks had underperformed due to poor management decisions ts2.tech ts2.tech. Within weeks, Comerica’s management began formally exploring strategic options, leading to the Fifth Third deal. HoldCo’s founders Vik Ghei and Misha Zaitzeff explained that many regional bank CEOs were overpaid and under-delivering – and they vowed to “shame” boards into action (via proxy fights if necessary) intellectia.ai ts2.tech. After Comerica, HoldCo moved on: it
31 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Rocket Companies Stock Blasts Off After $14B Mega-Merger – Will RKT Keep Soaring?

Rocket Companies (RKT) Stock Soars after $14B Mortgage Mega-Merger and Earnings Beat – What’s Next?

Stock Performance and Recent Moves Rocket Companies (NYSE: RKT) has been one of 2025’s surprise gainers in the mortgage sector. Its shares peaked in the low-$20s in early October on merger excitement, but have since pulled back into the mid-$16s ts2.tech stockanalysis.com. On Oct. 29 the stock slid about 7% (closing $16.24) before jumping ~5% in after-hours trading on Oct. 30 after the earnings beat stockanalysis.com investing.com. Even after the recent dip, RKT trades far above last year’s ~$10 low ts2.tech. For context, its 52-week range is roughly $10.06–$22.55 reuters.com. Investors have noted the stock’s volatility – Reuters data show
30 October 2025
 ·  ·  ·  ·  ·  ·  · 
Terex (TEX) Stock Crashes 18% on Surprise REV Group Merger News

Terex (TEX) Stock Crashes 18% on Surprise REV Group Merger News

In-Depth Analysis Terex’s stock slump on Oct. 30 came amid two shocks: mixed Q3 earnings results and a transformational merger announcement. After a previous close near $56, shares briefly traded in the mid-$40s, reflecting roughly an 18% intraday fall stockanalysis.com ts2.tech. Ts2.tech noted that “Terex fell ~18%” after the quarter (“weaker revenue”) news ts2.tech, a move echoed by institutional traders and option activity. By afternoon, volume had spiked and the stock was well below pre-earnings levels. For context, the 52-week range is $31.53–$58.66 stockanalysis.com, so even after the drop, shares remain above their 2025 low (around $32 last winter) but
30 October 2025
 ·  ·  ·  ·  ·  · 
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Bidding War Sends Metsera Shares Higher Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash (about $4.9B) plus up to $22.50 in contingent payments sec.gov. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatment sec.gov. Metsera CEO Whit Bernard called the deal “an excellent outcome for our shareholders” and praised the chance to “realize the promise of improved human health at scale” under Pfizer’s wing sec.gov. On Oct. 30, Novo Nordisk dramatically entered the fray with
30 October 2025
 ·  ·  ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolio reuters.com. According to MarketScreener (Dow Jones Newswires), the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRs marketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront (about $28.50/share) plus CVRs, for up to ~$7.3B ts2.tech reuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of
30 October 2025
 ·  ·  ·  ·  ·  · 
Alaska-Hawaiian Merger Takes Off: Single Operating Certificate and More

Alaska-Hawaiian Merger Takes Off: Single Operating Certificate and More

What This Means for Travelers Behind the scenes, Alaska’s takeoff toward full integration will be mostly transparent to customers. Travel itineraries and loyalty points carry over automatically, and the Hawaiian brand on island‑only routes remains in place airlinegeeks.com. Flight numbers and booking codes have already switched: passengers who booked on HA numbers need do nothing – their flights are now AS flights beatofhawaii.com. Free Wi‑Fi via Starlink (when installed) and an expanded network will be the tangible benefits in the cabin. As Alaska’s CEO put it, the goal is “one combined airline” in terms of systems, safety and service, without
29 October 2025
 ·  ·  ·  · 
Pepsi Bottler Goes Boozy: Varun Beverages Surges on Carlsberg Beer Deal & Q3 Profit Jump

Pepsi Bottler Goes Boozy: Varun Beverages Surges on Carlsberg Beer Deal & Q3 Profit Jump

Varun Beverages’ Big Pivot: From Colas to Carlsberg After decades of selling PepsiCo sodas and bottled water, Varun Beverages is making a bold pivot into booze. The company’s board on Wednesday approved adding alcoholic drinks to its business scope, a strategic move to diversify beyond soft drinks. “In response to the growing popularity of Ready To Drink (RTD) and [a] variety of alcoholic beverages, VBL sees an opportunity for expansion into [this] business… including beer, wine, liquor, brandy, whisky, gin, rum, [and] vodka in India & abroad,” the company said in a statement ndtvprofit.com. In other words, the Pepsi bottler will now
29 October 2025
 ·  ·  ·  · 
1 … 4 5 6 7 8 … 12
Go toTop